0001493152-26-013475
SEC filingFiscal 2025 was a commercial transition year for Scienture Holdings, marked by strong top-line growth offset by targeted operating investments to scale its commercial and pipeline capabilities.
The FY2025 operating loss of $42.6M and net loss of $41.5M reflect elevated levels of operating investment across the business as the company transitions from a clinical-stage to commercial-stage entity. These investments are targeted at building the scalable operational infrastructure required to support expanded commercial activity across the product portfolio. Professional fees increased year-over-year largely due to higher external consulting costs related to commercialization activities, SEC compliance work, and completed corporate actions, while accounting and legal expenses also rose driven by incremental costs associated with the year-end audit, public company SEC filings, and ongoing legal matters.
Management continues to evaluate potential strategic transactions and partnerships to accelerate product development and commercialization across the entire pipeline. The company expects to launch its second commercial product, REZENOPY™, in the second quarter of 2026, which will add a second recurring revenue stream to complement ARBLI™ sales, which are expected to grow throughout 2026. The company has confirmed it expects to fund all planned operations for at least the next twelve months using existing cash balances and projected revenue from its commercial product lines.